Alphatec Holdings, Inc. (ATEC) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Alphatec said its total addressable market is about $10 billion and it is currently slightly under 10% penetrated, leaving room for outsized growth versus a low- to mid-single-digit market growth rate. Management also highlighted the $1 billion lateral surgery segment as a key faster-growing opportunity and said the company has the ability to strengthen its balance sheet. The remarks were strategic and constructive, but no new financial results or guidance were disclosed.

Analysis

ATEC is signaling a classic scale-to-margin inflection: when a company is still only modestly penetrated in a large, fragmented procedure market, the next leg of upside usually comes less from “market growth” and more from mix shift, surgeon conversion, and better operating leverage. The second-order implication is that competitors with broader but slower-moving portfolios may lose share in the fastest-growing subsegments before the market notices it in top-line data. That dynamic tends to reward the pure-play leader for longer than valuation models assume, because the gain is not linear—it compounds as clinical adoption improves and sales productivity rises.

The balance-sheet comment matters because it reduces the probability that growth must be funded via dilution or expensive convert issuance, which has been a common overhang in medtech names with strong growth but weak capital structures. If management can de-risk leverage while maintaining growth, the market can re-rate the equity on both quality and durability of earnings, not just revenue momentum. The key reversal risk is any deceleration in procedure conversion rates: in this kind of category, even a small hiccup in surgeon adoption or reimbursement scrutiny can compress the multiple faster than the fundamentals deteriorate.

The contrarian angle is that the market may be underestimating how concentrated the upside is in a handful of clinical and commercial milestones over the next 2-3 quarters. If those milestones land, this can move like a growth medtech rerating; if they miss, the stock can derate like a leveraged small-cap healthcare story. The setup is therefore asymmetric: upside is driven by sustained share gains and capital-structure improvement, while downside comes from any evidence that growth is being bought with excess spending rather than generated by operating momentum.

Key Decisions for Investors

• Long ATEC on a 3-6 month horizon into the next operating update; target a rerating if growth remains above market and leverage trends down. Risk: a single quarter of decelerating procedure growth can cut multiple expansion quickly.
• Buy ATEC calls 1-2 quarters out rather than stock if you want convexity into catalyst windows; this is a better expression if you believe the market is underpricing an earnings/re-rating event.
• Pair trade: long ATEC / short a slower-growth, broader spine/orthopedic peer basket over the next 6 months to isolate share-gain alpha. Best if you expect product-driven adoption to outrun category growth.
• If ATEC rallies sharply before the next balance-sheet milestone, trim into strength: the stock’s upside is most sensitive to the first credible evidence of deleveraging, so pre-positioning is cleaner than chasing after confirmation.
• For conservative accounts, wait for confirmation in procedures and leverage before adding size; the risk/reward improves materially once the market sees both growth and capital discipline in the same print.